Thiazole-Bearing 4-Thiazolidinones as New Anticonvulsant Agents
Open Access
- 24 March 2020
- journal article
- research article
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 88 (1), 16
- https://doi.org/10.3390/scipharm88010016
Abstract
Here, we describe the synthesis and anticonvulsant activity of thiazole-bearing hybrids based on 2-imino-4-thiazolidinone and 2,4-dioxothiazolidine-5-carboxylic acid cores. The structure of target compounds was based on the following: (i) A combination of two thiazole cores; (ii) similarity to ralitolin’s structure; (iii) the compliance with structural requirements for the new anticonvulsants. Target compounds were synthesized via known approaches based on Knoenavegel reaction, alkylation reaction, and one-pot three-component reaction. Anticonvulsant properties of compounds were evaluated in two different models—pentylenetetrazole-induced seizures and maximal electroshock seizure tests. Among the tested compounds 5Z-(3-nitrobenzylidene)-2-(thiazol-2-ylimino)-thiazolidin-4-one Ib, 2-[2,4-dioxo-5-(thiazol-2- ylcarbamoylmethyl)-thiazolidin-3-yl]-N-(2-trifluoromethylphenyl)acetamide IId and (2,4-dioxo-5- (thiazol-2-ylcarbamoylmethylene)-thiazolidin-3-yl)acetic acid ethyl ester IIj showed excellent anticonvulsant activity in both models. The directions of compounds modification based on SAR aspects were discussed. The results of the study provide a basis for further study of the anticonvulsant properties of selected thiazole-thiazolidinones.Keywords
This publication has 50 references indexed in Scilit:
- Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysisZeitschrift für Neurologie, 2017
- Recent developments with rhodanine as a scaffold for drug discoveryExpert Opinion on Drug Discovery, 2017
- 5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistryEuropean Journal of Medicinal Chemistry, 2017
- Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset SeizuresDrugs in R&D, 2017
- Perampanel: A Review in Drug-Resistant EpilepsyDrugs, 2015
- Adverse effects of antiepileptic drugsThe Lancet Neurology, 2012
- The mechanism of action of retigabine (ezogabine), a first‐in‐class K+ channel opener for the treatment of epilepsyEpilepsia, 2012
- Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic StrategiesEpilepsia, 2010
- The epidemiology of epilepsy in Europe – a systematic reviewEuropean Journal of Neurology, 2005
- Patients with Refractory SeizuresThe New England Journal of Medicine, 1999